420 abstracts found.



Results filter

“I thought there would have been pain” A qualitative investigation of patients’ experiences of the route to, and diagnosis of, head and neck cancer.

Year:

Session type:

Jennifer Deane1,Joanne Patterson1,Linda Sharp1
1Newcastle University

Do Neutrophil Counts Pre-chemotherapy Treatment provide Clinical Value.

Year:

Session type:

Pinkie Chambers1,Li Wei2,Yogini Jani3,Ian Wong4
1UCLH NHS Foundation Trust,2UCL School of Pharmacy,3UCL/UCLH Centre for Medicines Optimisation Research and Education,4UCL Research Department of Pharmacy Practice

PLGA-Disulfiram microparticles inhibit NF-κB and PD-L1 pathway and reverse chemoresistance induced by mesothelioma stem cells.

Year:

Session type:

Garima Tyagi1
1Wolverhampton university

Treatment and survival in non-metastatic muscle invasive bladder cancer: analysis of a national patient cohort.

Year:

Session type:

Joseph John1,Mohini Varughese2,Nicola Cooper3,Kwok Wong3,Luke Hounsome3,Sarah Treece4,Susan Harden5
1Taunton and Somerset NHS Foundation Trust, Taunton, UK,2Taunton and Somerset NHS Foundation Trust,3National Cancer Registration and Analysis Service, Public Health England,4North West Anglia NHS Foundation Trust,5Cambridge University Hospitals NHS Foundation Trust

Waiting for a miracle or best medical practice? End-of-life medical ethical dilemmas in Bahrain

Year:

Session type:

Barrak Almoosawi1,Sayed Alwadaei1,Hani Humaidan2,Susan Dovey3
1University of Edinburgh,2SMC,3RCSI Bahrain

Engineered 3D-microtumours for personalized cancer therapy

Year:

Session type:

Nobina Mukherjee1,Prof. Hagan Bayley1
1University of Oxford

Capivasertib plus fulvestrant versus placebo plus fulvestrant in metastatic ER positive breast cancer (FAKTION): A randomised, double-blind, placebo-controlled, phase II trial

Year:

Session type:

Robert Jones1,Margherita Carucci2,Angela Casbard2,Rachel Butler3,Catherine Bale4,Fouad Alchami5,Pavel Bezecny6,Johnathan Joffe7,Sarah Moon8,Chris Twelves9,Ramachandran Venkitaraman10,Simon Waters1,Sacha Howell11
1Velindre University NHS Trust, Cardiff, UK,2Cardiff University, Cardiff, UK,3North Bristol NHS Trust, Bristol, UK,4Betsi Cadwaladr University Health Board, Bangor, UK,5Department of Cellular Pathology, University Hospital of Wales, Cardiff, UK,6Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, UK,7Royal College of Physicians of London, London, UK,8University Hospitals of Morecambe Bay NHS Trust, Milnthorpe Cumbria, UK,9University of Leeds and St. James's Institute of Oncology, Leeds, UK,10The Ipswich Hospital NHS Trust, Ipswich, UK,11The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK

Uncovering the long tail of oesophageal cancer driver genes for patient stratification

Year:

Session type:

Lorena Benedetti1,Thanos Mourikis1,Elisabeth Foxall1,Damjan Temelkovski1,Joel Nulsen1,Juliane Perner2,Matteo Cereda3,Christopher Yau4,Rebecca Fitzgerald2,Michael Howell1,Paola Scaffidi1,Francesca Ciccarelli1
1The Francis Crick Institute, London, UK,2University of Cambridge, Cambridge, UK,3Italian Institute for Genomic Medicine, Torino, Italy,4University of Birmingham, Birmingham, UK

Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (MBM; CheckMate 204)

Year:

Session type:

Hussein Tawbi1,Peter Forsyth2,F. Stephen Hodi3,Christopher Lao4,Stergios Moschos5,Omid Hamid6,Michael B. Atkins7,Karl Lewis8,Reena P. Thomas9,John A. Glaspy10,Sekwon Jang11,Alain Algazi12,Nikhil I. Khushalani2,Michael A. Postow13,Anna C. Pavlick14,Marc Ernstoff15,David A. Reardon3,Agnes Balogh16,Jasmine Rizzo16,Kim Margolin17
1University of Texas MD Anderson Cancer Center, Houston, US,2Moffitt Cancer Center and Research Institute, Tampa, US,3Dana-Farber Cancer Institute, Boston, US,4University of Michigan, Ann Arbor, US,5University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, US,6The Angeles Clinic and Research Institute, Los Angeles, US,7Georgetown Lombardi Comprehensive Cancer Center, Washington, US,8University of Colorado Comprehensive Cancer Center, Aurora, US,9Stanford University Hospital, Stanford, US,10Jonsson Comprehensive Cancer Center University of California, Los Angeles, US,11Inova Schar Cancer Institute, Falls Church, US, Virginia Commonwealth University, Richmond, US,12University of California–San Francisco, San Francisco, US,13Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, US,14New York University Langone Medical Center, New York, US,15Roswell Park Cancer Institute, Buffalo, US,16Bristol-Myers Squibb, New York, US,17City of Hope, Duarte, US

Combination of caloric restriction and lysine-specific demethylase 1 (LSD1) inhibition in the treatment of acute myeloid leukemia

Year:

Session type:

Rani Pallavi1,Luca Mazzarella1,Tiphanie Durfort1,Elena Gatti1,Bruno Achutti Duso1,Massimo Stendardo1,Luciano Giaco1,Ciro Mercurio2,Mario Varasi2,Marco Giorgio1,Saverio Minucci1,Pier Giuseppe Pelicci1
1European Institute of Oncology,2FIRC Institute of Molecular Biology

Safety and efficacy of 12 mg/d lenvatinib (LEN) in patients with unresectable hepatocellular carcinoma (uHCC) and bodyweight >80 kg in REFLECT

Year:

Session type:

Arndt Vogel1,Masatoshi Kudo2,Ann-Lii Cheng3,Max W. Sung4,Richard S. Finn5,Albert Y. Lin6,Ghassan K. Abou-Alfa7,Angel Alsina8,Valeriy Breder9,Niall Tebbutt10,Pia Osterlund11,C. J. Yen12,Min Ren13,Soamnauth Misir13,Corina E. Dutcus13,Daniel Palmer14,Philippe Merle15,Matthias Pinter16,TR Jeffry Evans17
1Hannover Medical School,2Kindai University School of Medicine,3National Taiwan University Hospital,4Tisch Cancer Institute at Mount Sinai,5Geffen School of Medicine, UCLA Medical Center,6VA Palo Alto Health Care System,7Memorial Sloan Kettering Cancer Center,8Tampa General Hospital,9N.N. Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation,10Olivia Newton-John Cancer Centre,11Tampere University and Central Hospital,12National Cheng Kung University Hospital,13Eisai Inc.,14University of Liverpool, Liverpool,15CHU de Lyon -Hospital La Croix-Rousse,16Medical University of Vienna,17University of Glasgow

Outcomes in patients age 70 and above treated with radical radiotherapy for Head & Neck Cancer

Year:

Session type:

Saurabh Borgaonkar1,Lisa Hay1,Claire Paterson1,Derek Grose1,Carolynn Lamb1,Stephano Schipani1,Christina Wilson1,Allan James1,Maureen Thomson1
1Beatson

Body composition and chemotherapy toxicity in women with early breast cancer: The Cando-3 study

Year:

Session type:

Ramsey Cutress1
1Faculty of Medicine, University of Southampton

Cachexia-related biomarkers predict shortened survival and treatment-related adverse outcomes in a population receiving palliative chemotherapy for lung cancer

Year:

Session type:

Joanna Bowden1,Linda Williams2,Amanda Swan3,Richard Skipworth4,Marie Fallon2
1NHS Fife, Kirkcaldy, UK, University of Edinburgh, Edinburgh, UK, University of St Andrews, St Andrews, UK,2University of Edinburgh, Edinburgh, UK,3NHS Fife, Kirkcaldy, UK ,4NHS Lothian, University of Edinburgh, Edinburgh, UK

Cancer Quality of Life Metric Project – Lessons learned from an implementation pilot

Year:

Session type:

Alice Simon1,Sarah Gelcich2,Adam Glaser3,Andria Hanbury4,Luke Hounsome5,Jane Maher6,Erik Mayer7,Alison Richardson8,Simon Rogers9,Lesley Smith10,Galina Velikova2,and the NHS England Cancer Quality of Life Working and Steering Groups10
1NHS England, London UK,2University of Leeds, Leeds, UK,3University of Leeds,4York Health Economics Consortium, York, UK,5Public Health England,6Macmillan Cancer Support, London UK, Mount Vernon Cancer Centre, Northwood, UK,7Imperial College Healthcare NHS Trust, London, UK, The Royal Marsden NHS Foundation Trust, London, UK,8University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK,9Aintree University Hospital NHS Foundation Trust, Liverpool, UK,10NHS England, London, UK

Meat intake and cancer risk: prospective analyses in UK Biobank

Year:

Session type:

Anika Knuppel1,Keren Papier1,Georgina K. Fensom1,Paul N. Appleby1,Julie A. Schmidt1,Tammy Y. N. Tong1,Ruth C. Travis1,Timothy J. Key1,Aurora Perez-Cornago1
1Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford

Evaluation of older patients in early phase clinical trials

Year:

Session type:

Jessica Lowe1,Rosie Lauste2,Tine Descamps3,Matthew Krebs1,Donna Graham1,Fiona Thistlethwaite1,Louise Carter1,Natalie Cook1
1The Christie NHS Foundation Trust, Manchester, UK,2University of Manchester, Manchester, UK,3Cancer Research UK, London, UK

How representative are patients responding to the Cancer Patient Experience Survey (2010-2014) of the wider cancer population in England? Analyses for breast, prostate, lung and colorectal cancer

Year:

Session type:

Saleh Alessy1,Elizabeth Davies1,Margreet Lüchtenborg1
1King's College London

Exploring the causal role of the human gut microbiome on colorectal cancer: Application of Mendelian randomization

Year:

Session type:

Kaitlin Wade1,Long Nguyen2,Amit Joshi2,Robert Carreras-Torres3,Andrew Chan2,Marc Gunter4,Yi Lin5,Graham Casey6,Jane Figueiredo7,Stephen Gruber8,Jochen Hampe9,Heather Hampel10,Mark Jenkins11,Temitope Keku12,Ulrike Peters13,Catherine Tangen14,Anna Wu15,David Hughes1,Malte Rühlemann16,Jeroen Raes17,Nicholas Timpson1

1MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School,2Massachusetts General Hospital,3IDIBELL Bellvitge Biomedical Research Institute,4International Agency for Research on Cancer,5Fred Hutchinson Cancer Research Center,6Center for Public Health Genomics,7Department of Medicine, Samuel Oschin Comprehensive Cancer Institute,8Department of Preventive Medicine, USC Norris Comprehensive Cancer Center,9Department of Medicine I, University Hospital Dresden,10Division of Human Genetics, Department of Internal Medicine, The Ohio State University,11Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health,12Center for Gastrointestinal Biology and Disease, University of North Carolina,13Public Health Sciences Division, Fred Hutchinson Cancer Research Center,14SWOG Statistical Center, Fred Hutchinson Cancer Research Center,15University of Southern California,16Institute of Clinical Molecular Biology, Christian Albrechts University of Kiel,17Center for Microbiology, VIB, Department of Microbiology and Immunology, Rega Instituut


Hospital activity before and after diagnosis of monoclonal gammopathy of undetermined significance (MGUS)

Year:

Session type:

Maxine Lamb1,Eleanor Kane1,Alexandra Smith1,Eve Roman1

1University of York, York, UK